Backgrounds: Brachytherapy is the only therapy for in-stent restenosis (ISR) proven to be effective in randomized clinical trials. There is a limited experience in Sirolimus-Eluting Stent (SES) for ISR. We performed this study to evaluate the clinical outcomes of SES for real world ISR. Methods: A total of 33 patients with 35 ISR (male; 67.6%, mean age; 60.6) (LAD=60.0%, LCX=20.0%, RCA=17.1%, LM=2.9%) (focal=20.0%, diffuse intrastent=34.3%, proliferative=17.1%, total occlusion=28.6%) were treated with SES after balloon predilation. We evaluated immediate and 6-month clinical results and 6 month angiography. Results: See table for the clinical results. Conclusion: Treatment of ISR with SES is safe and feasible without (sub)acute thrombosis.